22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The withdrawal liability case of the year came to an anticlimactic end on Monday, September 16, 2019...
Read More >
As pretty much expected, the Federal Reserve cut interest rates a quarter point again yesterday, its...
Read More >
- Most defined benefit (DB) pension schemes in the UK are affected by the High Court decision in Oct...
Read More >
The “4-Plex Bill” Meant to Address the Housing Crisis Couldn’t Muster Enough Support - Much to t...
Read More >
On September 3, 2020, the U.S. Department of Justice Antitrust Division released a revised Merger Re...
Read More >
I read a very interesting article in the Epstein Becker Wage & Hour Defense Blog, whose sentiments I...
Read More >